Clinical trials: Ophthalmic Solutions
Allergic Conjunctivitis
Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
The purpose of this study is to evaluate the efficacy of AC-150 compared to vehicle and its components in the prevention of the signs and symptoms of allergic conjunctivitis in Enviro-CAC™ Model.
- Trial name
- NCT01134328
- Testing
- AC-150 Combo, AC-150A 0.1%, AC-150B 0.005%
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Aciex Therapeutics, Inc.
Refractive Error
Comparison of Lotrafilcon B Lenses With Different Packaging Solutions
The purpose of this study is to evaluate AIR OPTIX® plus HYDRAGLYDE® (AOHG) contact lenses compared to AIR OPTIX® AQUA (AOA) contact lenses in overall lens fit.
- Trial name
- NCT02699684
- Testing
- Lotrafilcon B contact lenses with EOBO-41, Lotrafilcon B contact lenses, Hydrogen peroxide-based lens care solution
- Volunteers
- 82 people
- Sponsor
- Alcon Research
Allergic Conjunctivitis
ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
- Trial name
- NCT03494504
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- 7 sites in United States
- Volunteers
- 318 people
- Sponsor
- Aldeyra Therapeutics, Inc.
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension
Firecrest study is evaluating the intraocular pressure (IOP)-lowering effect, safety, and tolerability of Qlaris' preservative free [PF], fixed-dose combination [FDC] investigational product (IP) in subjects with open-angle…
- Trial name
- Firecrest (NCT07354516)
- Testing
- QLS-111-FDC, Latanoprost (0.005%)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Qlaris Bio, Inc.
Dry Eye Disease (DED), Keratoconjunctivitis Sicca
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
- Trial name
- NCT07078955
- Testing
- BRM421 Ophthalmic Solution, 0.03%, Artificial Tear, BRM421 Ophthalmic Solution, 0.06%
- Where
- Taiwan
- Volunteers
- 99 people
- Sponsor
- BRIM Biotechnology Inc.
Cataracts
Comparison of Centurion® Vision System With Balanced Tip and the Infiniti® Vision System With the Mini Flared Kelman (MFK) Tip During Cataract Extraction Surgery of Hard Lenses
The purpose of this study is to demonstrate that the Centurion® Vision System (CVS) used with the 45° Balanced Tip will result in less Cumulative Dissipated Energy (CDE) than the lnfiniti® Vision System (IVS) used with the 45°…
- Trial name
- NCT02502526
- Testing
- Centurion® Vision System, 45° Balanced Tip, Centurion® Vision System, 45° MFK Tip, lnfiniti® Vision System, 45° MFK Tip
- Volunteers
- 231 people
- Sponsor
- Alcon Research
Healthy Volunteers
Efficacy, Safety and Tolerability Study of Chloroprocaine 3% Gel Eye Drops in Healthy Volunteers
The study assess efficacy, safety and tolerability of Chloroprocaine 3% ophthalmic gel in healthy volunteers.
- Trial name
- NCT04753710
- Testing
- Ocular gel
- Where
- Austria
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Sintetica SA
Glaucoma, Ocular Hypertension
Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteolol and latanoprost in…
- Trial name
- NCT02108288
- Testing
- OPC-1085EL ophthalmic solution, Carteolol long-acting ophthalmic solution, Latanoprost ophthalmic solution
- Where
- Japan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Dry Eye
Dry Eye Disease Study With Brimonidine
To evaluate the tolerability and preliminary efficacy of Brimonidine eye drops (with and without corticosteroid eye drops) for the treatment of Dry Eye Disease (DED).
- Trial name
- NCT03418727
- Testing
- Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose
- Where
- 3 sites in United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ocugen
Healthy Volunteers
Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers
The primary objective of this study is to assess the safety and tolerability of a single short-term and a multiple dose scheme of rhNGF when administered as eye drops in healthy subjects of Japanese ethnicity.
- Trial name
- NCT03836859
- Testing
- rhNGF 20μg/mL
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Dompé Farmaceutici S.p.A
Dry Eye Disease
Safety and Efficacy of ST-100 (Vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed With Dry Eye Disease (DED)
A Phase 3 Multi-Center, Randomized, Double Masked, Vehicle Controlled Study to Assess the Safety and Efficacy of ST-100 (vezocolmitide) Ophthalmic Solution 60 μg/ml Ophthalmic Solution in Subjects Diagnosed with Dry Eye Disease…
- Trial name
- NCT06178679
- Testing
- ST-100 (vezocolmitide), Vehicle
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- ORA, Inc.
Age-related Macular Degeneration
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab.
- Trial name
- MAKO (NCT02727881)
- Testing
- Squalamine lactate ophthalmic solution, 0.2%, ranibizumab
- Where
- 118 sites in United States
- Volunteers
- 230 people
- Sponsor
- Ohr Pharmaceutical Inc.
Fuchs' Endothelial Corneal Dystrophy
Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.
- Trial name
- NCT04250207
- Testing
- K-321 Solution
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 65 people
- Sponsor
- Kowa Research Institute, Inc.
Allergic Conjunctivitis
Study to Assess the Safety, Tolerability and Efficacy of Bilastine Ophthalmic Solution 0.6% in Children
This is a multi-centre, randomised, double blind, placebo-controlled, parallel-group, phase III study to assess the safety, tolerability and efficacy of Bilastine ophthalmic solution 0.6% in children with a documented history of…
- Trial name
- NCT04810390
- Testing
- Bilastine
- Where
- 18 sites in Spain
- Volunteers
- 59 people
- Sponsor
- Faes Farma, S.A.
Cataract
Safety and Efficacy of Next Generation Ophthalmic Irrigating Solution Compared to BSS Plus
The purpose of this study is to determine the safety and efficacy of Next Generation Ophthalmic Irrigating Solution (NGOIS) compared to BSS Plus for use during cataract extraction and intra-ocular lens (IOL) implantation.
- Trial name
- NCT00333268
- Testing
- Next Generation Ophthalmic Irrigating Solution (NGOIS), BSS Plus
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Alcon Research
Age-Related Macular Degeneration
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate anatomical and functional effect of combination therapy of Squalamine Lactate Ophthalmic Solution, 0.2% administered twice daily with monthly ranibizumab intravitreal injections in…
- Trial name
- NCT02511613
- Testing
- Squalamine Lactate Ophthalmic Solution, 0.2%, ranibizumab
- Where
- 4 sites in United States
- Sponsor
- Ohr Pharmaceutical Inc.
Dry Eye
Comparative Efficacy of SYSTANE® ULTRA vs Optive™ in Improving Tear Film Break-up Time
The primary objective of this study is assess the Tear Film break-up time (TBUT) in mild to moderate dry eye subjects.
- Trial name
- NCT01417013
- Testing
- Systane Ultra, Optive
- Volunteers
- healthy volunteers welcome
- Sponsor
- Alcon Research
Dry Eye
ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease
- Trial name
- OASIS-1 (NCT04899518)
- Testing
- ALY688 Ophthalmic Solution
- Where
- United States
- Volunteers
- 922 people
- Sponsor
- Allysta Pharmaceutical
Dry Eye Disease
Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.
The objective of this study is to compare the safety and efficacy of BRM421 OS to vehicle for the treatment of the signs and symptoms of dry eye disease.
- Trial name
- NCT05695781
- Testing
- BRM421 Ophthalmic Solution, Vehicle
- Where
- United States
- Volunteers
- 740 people
- Sponsor
- BRIM Biotechnology Inc.
Dry Eye
A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes
The objective of this study was to compare the safety and efficacy of 0.10% and 0.25% HL036 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- VELOS-1 (NCT03334539)
- Testing
- HL036 ophthalmic solution
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- HanAll BioPharma Co., Ltd.